Formation and toxicity of anesthetic degradation products

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 147-176

  Anders, M W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

1,1 difluoro 2 bromo 2 chloroethylene; Carbon monoxide; Compound A; Desflurane; Dichloroacetylene; Enflurane; Halothane; Isoflurane; Sevoflurane; Trichloroethylene

Indexed keywords

2 BROMO 2 CHLORO 1,1 DIFLUOROETHYLENE; 2,2 DIFLUORO 1 (TRIFLUOROMETHYL)VINYL FLUOROMETHYL ETHER; ACETYLENE DERIVATIVE; ANESTHETIC AGENT; CARBON MONOXIDE; DESFLURANE; DICHLOROACETYLENE; ENFLURANE; GLUTATHIONE; HALOTHANE; ISOFLURANE; SEVOFLURANE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG;

ANESTHESIA; ANESTHESIA MECHANISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHEMICAL REACTION KINETICS; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION KINETICS; DRUG SAFETY; DRUG USE; ENZYME METABOLISM; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; REVIEW; TOXICITY;

ANESTHETICS; ANIMALS; HUMANS;

ANIMALIA;

EID: 13844315652     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095847     Document Type: Review

References (127)

1. Striker C, Goldblatt S, Warm IS, Jackson DE. 1935. Clinical experiences with the use of trichloroethylene in the production of over 300 analgesias and anesthesias. Curr. Res. Anesth. 14:68-71
2. Hewer CL. 1943. Further observations on trichloroethylene. Proc. R. Soc. Med. 36:463-65
3. McAuley J. 1943. Trichloroethylene and trigeminal anaesthesia. Br. Med. J. 2:713-14
4. Carden S. 1944. Hazards in the use of the closed-circuit technique for trilene anaesthesia. Br. Med. J. 1:319-20
5. Firth JB, Stuckey RE. 1945. Decomposition of trilene in closed circuit anaesthesia. Lancet 1:814-16
6. Ott E, Ottemeyer W, Packendorff K. 1930. Über das Dichlor-acetylen. Chem. Ber. 63:1941-44
7. Reichert D, Metzler M, Henschler D. 1980. Decomposition of the neuro- and nephrotoxic compound dichloroacetylene in the presence of oxygen: separation and identification of novel products. J. Environ. Pathol. Toxicol, 3:525-32
8. 14C-dichloroethyne in rats. Xenobiotica 21:905-16
9. Dekant W, Vamvakas S, Anders MW. 1994. Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate β-lyase pathway. Adv. Pharmacol. 27:115-62
10. Anders MW, Dekant W. 1998. Glutathione-dependent bioactivation of haloalkenes. Annu. Rev. Pharmacol. Toxicol. 38:501-37
11. Kanhai W, Dekant W, Henschler D. 1989. Metabolism of the nephrotoxin dichloroacetylene by glutathione conjugation. Chem. Res. Toxicol. 2:51-56
12. Elfarra AA, Jakobson I, Anders MW. 1986. Mechanism of S-(1,2-dichlorovinyl)glutathione-induced nephrotoxicity. Biochem. Pharmacol. 35:283-88
13. Völkel W, Dekant W. 1998. Chlorothioketene, the ultimate reactive intermediate formed by cysteine conjugate β-lyase-mediated cleavage of the trichloroethene metabolite S-(1,2-Dichlorovinyl)-L-cysteine, forms cytosine adducts in organic solvents, but not in aqueous solution. Chem. Res. Toxicol. 11:1082-88
14. Zhang T-L, Wang L, Hashmi M, Anders MW, Thorpe C, Ridge DP. 1995. Fourier-transform ion cyclotron resonance mass spectrometric evidence for the formation of α-chloroethenethiolates and thioketenes from chloroalkene-derived, cytotoxic 4-thiaalkanoates. Chem. Res. Toxicol. 8:907-10
15. Reichert D, Ewald D, Henschler D. 1975. Generation and inhalation toxicity of dichloroacetylene. Food Cosmet. Toxicol. 13:511-15
16. Reichert D, Liebaldt G, Henschler D. 1976. Neurotoxic effects of dichloroacetylene. Arch. Toxicol 37:23-38
17. Reichert D, Henschler D. 1978. Nephrotoxic and hepatotoxic effects of dichloroacetylene. Food Cosmet. Toxicol. 16: 227-35
18. Reichert D, Spengler U, Romen W, Henschler D. 1984. Carcinogenicity of dichloroacetylene: an inhalation study. Carcinogenesis 5:1411-20
19. Patel NJ, Fullone JS, Anders MW. 1993. Brain uptake of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene. Mol. Brain Res. 17:53-58
20. Patel N, Birner G, Dekant W, Anders MW. 1994. Glutathione-dependent biosynthesis and bioactivation of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of dichloroacetylene, in rat tissues and subcellular fractions. Drug Metab. Dispos. 22: 143-17
21. Lash LH, Anders MW. 1986. Cytotoxicity of S-(1,2-dichlorovinyl) glutathione and S-(1,2-dichlorovinyl)-L-cysteine in isolated rat kidney cells. J. Biol. Chem. 261:13076-81
22. Lash LH, Anders MW. 1987. Mechanism of S-(1,2-dichlorovinyl)-L-cysteine- and S-(1,2-dichlorovinyl)-L-homocysteine-induced renal mitochondrial toxicity. Mol. Pharmacol. 32:549-56
23. Stevens J, Hayden P, Taylor G. 1986. The role of glutathione conjugate metabolism and cysteine conjugate ®-lyase in the mechanism of S-cysteine conjugate toxicity in LLC-PK1 cells. J. Biol. Chem. 261: 3325-32
24. Reichert D, Neudecker T, Spengler U, Henschler D. 1983. Mutagenicity of dichloroacetylene and its degradation products trichloroacetyl chloride, trichloroacryloyl chloride, and hexachlorobutadiene. Mutat. Res. 117:21-29
25. Vamvakas S, Elfarra AA, Dekant W, Henschler D, Anders MW. 1988. Mutagenicity of amino acid and glutathione S-conjugates in the Ames test. Mutat. Res. 206:83-90
26. Vamvakas S, Dekant W, Schiffmann D, Henschler D. 1988. Induction of unscheduled DNA synthesis and micronucleus formation in Syrian hamster embryo fibroblasts treated with cysteine S-conjugates of chlorinated hydrocarbons. Cell Biol. Toxicol. 4:393-403
27. 1 cells-a comparative investigation with growth factors and 12-O- tetradecanoylphorbolacetate. Cell Biol. Toxicol. 9:1-13
28. Greim H, Wolff T, Höfler M, Lahaniatis E. 1984. Formation of dichloroacetylene from trichloroethylene in the presence of alkaline material-possible cause of intoxication after abundant use of chloroethylene-containing solvents. Arch. Toxicol. 56:74-77
29. Humphrey JH, McClelland M. 1944. Cranial-nerve palsies with herpes following general anaesthesia. Br. Med. J. 1:315-18
30. Lash LH, Nelson RM, Van Dyke RA, Anders MW. 1990. Purification and characterization of human kidney cytosolic conjugate β-lyase activity. Drug Metab. Dispos. 18:50-54
31. McCarthy RI, Lock EA, Hawksworth GM. 1994. Cytosolic C-S lyase activity in human kidney samples-relevance for the nephrotoxicity of halogenated alkenes in man. Toxicol. Indust. Health 10:103-12
32. Iyer RA, Anders MW. 1996. Cysteine conjugate β-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product Compound A in human, nonhuman primate, and rat renal cytosol and mitochondria. Anesthesiology 85:1454-61
33. Raventós J. 1956. The action of fluothane-a new volatile anesthetic. Br. J. Pharmacol. 11:394-409
34. Pohl LR, Kenna JG, Satoh H, Christ D, Martin JL. 1989. Neoantigens associated with halothane hepatitis. Drug Metab. Rev. 20:203-17
35. Pohl LR. 1990. Drug-induced allergic hepatitis. Semin. Liver Dis. 10:305-15
36. Raventós J, Lemon PG. 1965. The impurities in Fluothane: their biological properties. Brit. J. Anaesth. 37:716-37
37. Chapman J, Hill R, Muir J, Suckling CW, Viney DJ. 1967. Impurities in halothane: their identities, concentrations and determination. J. Pharm. Pharmacol. 19:231-39
38. Kodama G. 1973. Halothane impurities and decomposition of halothane by soda-lime. II. Analysis of halothane impurities. Hiroshima J. Anesth. 9:75-89
39. Sharp JH, Trudell JR, Cohen EN. 1979. Volatile metabolites and decomposition products of halothane in man. Anesthesiology 50:2-8
40. Cohen EN, Trudell JR, Edmunds HN, Watson E. 1975. Urinary metabolites of halothane in man. Anesthesiology 43:392-401
41. Denson DD, Ford DJ. 1979. How reactive are the reductive metabolites of halothane? Anesthesiology 51:S243
42. Wark H, Earl J, Chau DD, Overton J, Cheung HTA. 1990. A urinary cysteine-halothane metabolite: validation and measurement in children. Br. J. Anaesth. 64:469-73
43. Finkelstein MB, Dekant W, Kende AS, Anders MW. 1995. α-Thiolactones as novel intermediates in the cysteine conjugate β-lyase-catalyzed bioactivation of bromine-containing cysteine S-conjugates. J. Am. Chem. Soc. 117:9590-91
44. Finkelstein MB, Dekant W, Anders MW 1996. Cysteine conjugate β-lyase-catalyzed bioactivation of bromine-containing cysteine S-conjugates: stoichiometry and formation of 2,2-difluoro-3-halothiiranes. Chem. Res. Toxicol. 9: 227-31
45. Shim J-Y, Richard AM. 1997. Theoretical evaluation of two plausible routes for bioactivation of S-(1,1-difluoro-2,2-dihaloethyl)-L-cysteine conjugates: thiirane vs thionoacyl fluoride pathway. Chem. Res. Toxicol. 10:103-10
46. 19F NMR evidence for stereochemical control of the reaction. Biochemistry 24: 5137-43
47. Commandeur JNM, Brakenhoff JPG, De Kanter FJJ, Vermeulen NPE. 1988. Nephrotoxicity of mercapturic acids of three structurally related 2,2-difluoroethylenes in the rat. Biochem. Pharmacol. 37:4495-504
48. Commandeur JNM, King LJ, Koymans L, Vermeulen NPE. 1996. Bioactivation of S-(2,2-dihalo-1,1-difluoroethyl)-L-cysteines and S-(trihalovinyl)-L-cysteines by cysteine S-conjugate β-lyase: indications for formation of both thionoacylating species and thiiranes as reactive intermediates. Chem. Res. Toxicol. 9: 1092-102
49. Finkelstein MB, Baggs RB, Anders MW. 1992. Nephrotoxicity of the glutathione and cysteine conjugates of 2-bromo-2-chloro-1,1-difluoroethene. J. Pharmacol. Exp. Ther. 261:1248-52
50. Garro AJ, Phillips RA. 1978. Mutagenicity of the halogenated olefin, 2-bromo-2-chloro-1,1-difluoroethylene, a presumed metabolite of the inhalation anesthetic halothane. Mutat. Res. 54:17-22
51. Edmunds HN, Baden JM, Simmon VF. 1979. Mutagenicity studies with volatile metabolites of halothane. Anesthesiology 51(5):424-29
52. Waskell L. 1979. Lack of mutagenicity of two possible metabolites of halothane. Anesthesiology 50:9-12
53. Sachdev K, Cohen EN, Simmon VF. 1980. Genotoxic and mutagenic assays of halothane metabolites in Bacillus subtilis and Salmonella typhimurium. Anesthesiology 53:31-39
54. Finkelstein MB, Vamvakas S, Bittner D, Anders MW. 1994. Structure-mutagenicity and structure-cytotoxicity studies on bromine-containing cysteine S-conjugates and related compounds. Chem. Res. Toxicol. 7:157-63
55. Dekant W, Vamvakas S, Berthold K, Schmidt S, Wild D, Henschler D. 1986. Bacterial ®-lyase mediated cleavage and mutagenicity of cysteine conjugates derived from the nephrocarcinogenic alkenes trichloroethylene, tetrachloroethylene and hexachlorobutadiene. Chem. Biol. Interact. 60:31-45
56. Wallin RF, Regan BM, Napoli MD, Stern IJ. 1975. Sevoflurane: a new inhalational anesthetic agent. Anesth. Analg. 54:758-66
57. Eger EI II. 1987. Stability of I-653 in soda lime. Anesth. Analg. 66:983-85
58. Strum DP, Johnson BH, Eger EI II. 1987. Stability of sevoflurane in soda lime. Anesthesiology 67:779-81
59. Hanaki C, Fujii K, Mono M, Tashima T. 1987. Decomposition of sevoflurane by sodalime. Hiroshima J. Med. Sci. 36:61-67
60. Mono M, Fujii K, Satoh N, Imai M, Kawakami T, et al. 1992. Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the by products. Anesthesiology 77:1155-64
61. 2 absorbants during low-flow anesthesia in surgical patients. Anesthesiology 77:1064-69
62. Bito H, Ikeda K. 1994. Closed-circuit anesthesia with sevoflurane in humans. Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology 80:71-76
63. Bito H, Ikeda K. 1994. Plasma inorganic fluoride and intracircuit degradation product concentrations in long-duration, low-flow sevoflurane anesthesia. Anesth. Analg. 79:946-51
64. Fang ZX, Eger EI II. 1995. Factors affecting the concentration of Compound A resulting from the degradation of sevoflurane by soda lime and Baralyme® in a standard anesthetic circuit. Anesth. Analg. 81:564-68
65. Fang ZX, Kandel L, Laster MJ, Ionescu P, Eger EI II. 1996. Factors affecting production of Compound A from the interaction of sevoflurane with Baralyme® and soda lime. Anesth. Analg. 82:1-7
66. Munday IT, Ward PM, Foden ND, Jones RM, Van Pelt FNAM, Kenna JG. 1996. Sevoflurane degradation by soda lime in a circle breathing system. Anaesthesia 51:622-26
67. Bito H, Ikeda K. 1995. Effect of total flow rate on the concentration of degradation products generated by the reaction between sevoflurane and soda lime. Brit. J. Anaesth. 74:667-69
68. Huang C, Venturella VS, Cholli AL, Venutolo FM, Silbermann AT, Vernice GG. 1989. Detailed investigation of fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether (Sevoflurane) and its degradation products. Part I: synthesis of fluorinated, soda lime induced degradation products. J. Fluorine Chem. 45:239-53
69. Kharasch ED, Hankins DC. 1996. P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A), a sevoflurane degradation product. Drug Metab. Dispos. 24:649-54
70. Kharasch ED, Thummel KE. 1993. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 79:795-807
71. Jin L, Baillie TA, Davis MR, Kharasch ED. 1995. Nephrotoxicity of sevoflurane Compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase. Biochem. Biophys. Res. Commun. 210:498-506
72. Jin L, Davis MR, Kharasch ED, Doss GA, Baillie TA. 1996. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1- (trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. Chem. Res. Toxicol. 9:555-61
73. Spracklin DK, Kharasch ED. 1996. Evidence for metabolism of fluoromethyl 2, 2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A), a sevoflurane degradation product, by cysteine conjugate β-lyase. Chem. Res. Toxicol. 9:696-702
74. Iyer RA, Anders MW. 1997. Cysteine conjugate β-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro1-propene (Compound A). Chem. Res. Toxicol. 10:811-19
75. Kharasch ED, Jubert C. 1999. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. Anesthesiology 91:1267-78
76. Uttamsingh V, Iyer RA, Baggs RB, Anders MW. 1998. Fate and toxicity of 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (Compound A)-derived mercapturates in male, Fischer 344 rats. Anesthesiology 89:1174-83
77. Iyer RA, Frink EJ Jr, Ebert TJ, Anders MW. 1998. Cysteine conjugate β-lyase-dependent metabolism of Compound A (2-(fluoromethoxy)-1,1,3,3,3- pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given Compound A. Anesthesiology 88:611-18
78. Altuntas TG, Kharasch ED. 2002. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and β-lyase-catalyzed metabolism. Drug Metab. Dispos. 30:148-54
79. Altuntas TG, Park SB, Kharasch ED. 2004. Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). Chem. Res. Toxicol. 17:435-45
80. Gonsowski CT, Laster MJ, Eger EI II, Ferrell LD, Kerschmann RL. 1994. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology 80:556-65
81. Gonsowski CT, Laster MJ, Eger EI II, Ferrell LD, Kerschmann RL. 1994. Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 80:566-73
82. Kandel L, Laster MJ, Eger EI II, Kerschmann RL, Martin J. 1995. Nephrotoxicity in rats undergoing a one-hour exposure to Compound A. Anesth. Analg. 81:559-63
83. Keller KA, Callan C, Prokocimer P, Delgado-Herrera L, Friedman MB, et al. 1995. Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 83:1220-32
84. Dohn DR, Leininger JR, Lash LH, Quebbemann AJ, Anders MW. 1985. Nephrotoxicity of 5-(2-chloro-1,1,2-trifluoroethyl)glutathione and 5-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine, the glutathione and cysteine conjugates of chlorotrifluoroethene. J. Pharmacol. Exp. Ther. 235:851-57
85. Koob M, Dekant W. 1990. Metabolism of hexafluoropropene. Evidence for bioactivation by glutathione conjugate formation in the kidney. Drug Metab. Dispos. 18:911-16
86. Odum J, Green T. 1984. The metabolism and nephrotoxicity of tetrafluoroethylene in the rat. Toxicol. Appl. Pharmacol. 76:306-18
87. Iyer RA, Baggs RB, Anders MW. 1997. Nephrotoxicity of the glutathione and cysteine conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1, 1,3,3,3-pentafluoro-1-propene (Compound A) in male, Fischer 344 rats. J. Pharmacol. Exp. Ther. 283:1544-51
88. Martin JL, Laster MJ, Kandel L, Kerschmann RL, Reed GF, Eger EI II. 1996. Metabolism of Compound A by renal cysteine-S-conjugate β-lyase is not the mechanism of Compound A-induced renal injury in the rat. Anesth. Analg. 82: 770-74
89. Martin JL, Kandel L, Laster MJ, Kerschmann RL, Eger EI II. 1997. Studies on the mechanism of nephrotoxicity of compound A in rats. J. Anesthesiol. 11:32-37
90. Njoku DB, Pohl LR, Sokoloski EA, Marchick MR, Borkowf CB, Martin JL. 1999. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats. Anesthesiology 90:458-69
91. Kharasch ED, Thorning D, Garton K, Hankins DC, Kilty GC. 1997. Role of renal cysteine conjugate β-lyase in the mechanism of Compound A nephrotoxicity in rats. Anesthesiology 86:160-71
92. Kharasch ED, Hoffman GM, Thorning D, Hankins DC, Kilty CG. 1998. Role of the renal cysteine conjugate β-lyase pathway in inhaled Compound A nephrotoxicity in rats. Anesthesiology 88:1624-33
93. Davis ME. 1988. Effects of AT-125 on the nephrotoxicity of hexachloro-1,3-butadiene in rats. Toxicol. Appl. Pharmacol. 95:44-52
94. de Céaurriz J, Ban M. 1990. Role of γ-glutamyltranspeptidase and β-lyase in the nephrotoxicity of hexachloro-1,3-butadiene and methyl mercury in mice. Toxicol. Lett. 50:249-56
95. Nash JA, King LH, Lock EA, Green T. 1984. The metabolism and disposition of hexachloro-1:3-butadiene in the rat and its relevance to nephrotoxicity. Toxicol. Appl. Pharmacol. 73:124-37
96. Lantum HB, Iyer RA, Anders MW. 2004. Acivicin-induced alterations in renal and hepatic glutathione concentrations and in g-glutamyltransferase activities. Biochem. Pharmacol. 67:1421-26
97. Altuntas TG, Zager RA, Kharasch ED. 2003. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1- (trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. Toxicol. Appl. Pharmacol. 193:55-65
98. Lash LH, Sausen PJ, Duescher RJ, Cooley AJ, Elfarra AA. 1994. Roles of cysteine conjugate β-lyase and S-oxidase in nephrotoxicity: studies with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine sulfoxide. J. Pharmacol. Exp. Ther. 269:374-83
99. Werner M, Birner G, Dekant W. 1996. Sulfoxidation of mercapturic acids derived from tri- and tetrachloroethene by cytochromes P450 3A: a bioactivation reaction in addition to deacetylation and cysteine conjugate β-lyase mediated cleavage. Chem. Res. Toxicol. 9:41-49
100. Birner G, Werner M, Ott MM, Dekant W. 1995. Sex differences in hexachlorobutadiene biotransformation and nephrotoxicity. Toxicol. Appl. Pharmacol. 132:203-12
101. Park SB, Osterloh JD, Vamvakas S, Hashmi M, Anders MW, Cashman JR. 1992. Flavin-containing monooxygenase-dependent stereoselective 5-oxygenation and cytotoxicity of cysteine S-conjugates and mercapturates. Chem. Res. Toxicol. 5:193-201
102. Terracini B, Parker VH. 1965. A pathological study on the toxicity of S-dichlorovinyl-L-cysteine. Food Cosmet. Toxicol. 3:67-74
103. Reichle FM, Conzen PF, Peter K. 2002. Nephrotoxicity of halogenated inhalational anaesthetics: fictions and facts. Eur. Surg. Res. 34:188-95
104. Reichle FM, Conzen PF. 2003. Halogenated inhalational anaesthetics. Best Pract. Res. Clin. Anaesthesiol. 17:29-46
105. Mazze RI. 1992. The safety of sevoflurane. Anesthesiology 77:1062-63
106. Eger EI II, Koblin DD, Bowland T, Ionescu P, Laster MJ, et al. 1997. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth. Analg. 84:160-68
107. Eger EI II, Gong D, Koblin DD, Bowland T, Ionescu P, et al. 1997. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth. Analg. 85:1154-63
108. Ebert TJ, Frink EJ Jr, Kharasch ED. 1998. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. Anesthesiology 88:601-10
109. Ebert TJ, Frink EJ, Kharasch ED. 1998. Absence of renal and hepatic toxicity following 8 hours of 1.25 MAC sevoflurane anesthesia in volunteers. Anesthesiology 100:1-2
110. Higuchi H, Sumita S, Wada H, Ura T, Ikemoto T, et al. 1998. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology 89:307-22
111. Obata R, Bito H, Ohmura M, Moriwaki G, Ikeuchi Y, et al. 2000. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesth. Analg. 91:1262-68
112. Groudine SB, Fragen RJ, Kharasch ED, Eisenman TS, Frink EJ, et al. 1999. Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane. J. Clin. Anesth. 11:201-7
113. Kharasch ED, Frink EJ Jr, Artru A, Michalowski P, Rooke GA, Nogami W. 2001. Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function. Anesth. Analg. 93:1511-20
114. Mazze RI, Callan CM, Galvez ST, Delgado-Herrera L, Mayer DB. 2000. The effects of sevoflurane on serum creatinine and blood urea nitrogen concentralions: a retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. Anesth. Analg. 90:683-88
115. Green T, Odum J, Nash JA, Foster JR. 1990. Perchloroethylene-induced rat kidney tumors: an investigation of the mechanisms involved and their relevance to humans. Toxicol. Appl. Pharmacol. 103:77-89
116. Moon RE, Ingram C, Brunner EA, Meyer AF. 1991. Spontaneous generation of carbon monoxide within anesthetic circuits. Anesthesiology 75:A873
117. Moon RE, Meyer AF, Scott DL, Fox E, Millington DS, Norwood DL. 1990. Intraoperative carbon monoxide toxicity. Anesthesiology 73:A1049
118. 2 anesthetic + dry absorbent. Anesthesia Patient Saf. Found. Newsl. 9:25-30
119. National Research Council CoMaBEoEP. 1977. Carbon Monoxide. Washington, DC: Natl. Acad. Sci.
120. Pankow D. 1996. Carbon monoxide formation due to metabolism of xenobiotics. In Carbon Monoxide, ed. DG Penney, pp. 25-43. Boca Raton: CRC Press
121. Fang ZX, Eger EI II, Laster MJ, Chortkoff BS, Kandel L, Ionescu P. 1995. Carbon monoxide production from degradation of desflurane, enflurane, isoflurane, halothane, and sevoflurane by soda lime and Baralyme®. Anesth. Analg. 80:1187-93
122. Baxter PJ, Kharasch ED. 1997. Rehydration of desiccated Baralyme prevents carbon monoxide formation from desflurane in an anesthesia machine. Anesthesiology 86:1061-65
123. Kharasch ED, Powers KM, Artru AA. 2002. Comparison of Amsorb®, sodalime, and Baralyme® degradation of volatile anesthetics and formation of carbon monoxide and Compound A in swine in vivo. Anesthesiology 96:173-82
124. Baxter PJ, Garton K, Kharasch ED. 1998. Mechanistic aspects of carbon monoxide formation from volatile anesthetics. Anesthesiology 89:929-41
125. le Noble WJ. 1974. Highlights of Organic Chemistry. New York: Marcel Dekker
126. Tzagoloff A, Wharton DC. 1965. Studies on the electron transport system. LXII. The reaction of cytochrome oxidase with carbon monoxide. J. Biol. Chem. 240:2628-33
127. Fenn WO. 1970. The burning of CO in tissues. Ann. NY Acad. Sci. 174:64-71